Update on cancer therapeutics最新文献_第9页

NSC-Numbers

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/S1872-115X(06)00076-4

引用次数: 0

Cross resistance of melanoma to trail-induced apoptosis and chemotherapy 黑色素瘤对药物诱导的细胞凋亡和化疗的交叉耐药

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.08.004

Xu Dong Zhang, Jing Jing Wu, Susan Gillespie, Jodie Borrow, Peter Hersey

{"title":"Cross resistance of melanoma to trail-induced apoptosis and chemotherapy","authors":"Xu Dong Zhang, Jing Jing Wu, Susan Gillespie, Jodie Borrow, Peter Hersey","doi":"10.1016/j.uct.2006.08.004","DOIUrl":"10.1016/j.uct.2006.08.004","url":null,"abstract":"<div>Melanoma is frequently resistant to a wide range of chemotherapeutic and biologic agents. In its early stages, it is also very immunogenic and gives rise to both T cell and antibody responses. Killing of melanoma by T cells involves induction of apoptosis through the mitochondrial pathway and shares common apoptotic pathways to that induced by chemotherapy. We considered it was therefore possible that prolonged exposure to the immune system may generate escape variants that are resistant to apoptosis induced by the immune system or by chemotherapy. This hypothesis was tested by generating melanoma cells that were resistant to TNF-related apoptosis inducing ligand (TRAIL), which is one of the mediators of apoptosis used by the immune system. Melanoma cells selected in this way were found to be resistant to apoptosis induced by cisplatin, vincristine and a histone deacetylase inhibitor. Melanoma cells resistant to these agents had low levels of pro-apoptotic Bcl-2 (BH3 only) proteins and high levels of activated ERK1/2 and Akt signal pathways. Inhibition of the latter pathways partially overcame some of the resistance to the chemotherapy agents but not to TRAIL. These results support the view that selection by the immune system may in part be responsible for resistance of melanoma to some chemotherapy commonly used against melanoma. Further study of the resistant mechanisms involved may provide insights into new treatment approaches in melanoma.</div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55737969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Abbreviations of Chemotherapeutic Combinations 化疗联合的缩写

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/S1872-115X(06)00074-0

引用次数: 0

Abbreviations of Drugs 药物简写

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/S1872-115X(06)00073-9

引用次数: 0

Lymphomas 淋巴瘤

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.08.008

Armando Santoro, Luca Castagna, Massimo Magagnoli

{"title":"Lymphomas","authors":"Armando Santoro, Luca Castagna, Massimo Magagnoli","doi":"10.1016/j.uct.2006.08.008","DOIUrl":"https://doi.org/10.1016/j.uct.2006.08.008","url":null,"abstract":"<div>The majority of patients with early-stage (IA–IIA) Hodgkin's disease (HD) can at present be cured by current available therapeutic options. Actually the “gold standard” for patients with early-stage HD is a combined approach consisting of a short-duration chemotherapy (e.g., two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVD) and low-dose (20–30 <!-->Gy) involved-field irradiation (IF-RT).The treatment of choice for advanced-stage HD is still represented by chemotherapy alone or followed by RT. At present, it is internationally accepted that ABVD should be the standard regimen.High-dose chemotherapy (HDC) with peripheral-blood stem-cell support (PBSCs) represents the treatment of choice for patients relapsing after chemotherapy, but, nevertheless, about 50% of transplanted patients relapse or progress after HDC.Regarding low- and high-grade non-Hodgkin's lymphomas, Rituximab associated or not to chemotherapy, is much more extensively used. In advanced low-grade lymphomas the role of immunochemotherapy has been definitively demonstrated in a phase III study, comparing eight courses of rituximab plus chemotherapy (CVP regimen) versus CVP alone at diagnosis. Three courses of CHOP plus Rituximab associated to involved fields radiotherapy (RT) is considered to be the standard treatment in localized high-grade lymphoma. In advanced disease patients, intensified CHOP-like regimen and new therapeutic agents have been tried to improve the clinical results in newly diagnosed patients with encouraging results. Finally, several studies confirmed the usefulness of prognostic scores as IPI for high-grade lymphoma and FLIPI for follicular lymphoma, and the usefulness of PET in the staging of lymphomas.</div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.08.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137161441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiogenesis inhibitors in clinical oncology 血管生成抑制剂在临床肿瘤学中的应用

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.08.006

Daniel J. George, Cassandra Moore

引用次数: 5

Biological Abbreviations 生物的缩写

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/S1872-115X(06)00075-2

引用次数: 0

Genitourinary malignancies 生殖泌尿系恶性肿瘤

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.08.007

Shandra S. Wilson

引用次数: 0

Systemic therapy for gynecological neoplasms: Ovary, cervix and endometrium 妇科肿瘤的全身治疗:卵巢、子宫颈和子宫内膜

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.06.004

Sergio Pecorelli , Roberto Angioli , Brunella Pasinetti , Giancarlo Tisi , Franco Odicino

引用次数: 19

Thymidylate synthase inhibitors 胸腺苷酸合成酶抑制剂

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.09.001

Stephen P. Ackland , Stephen J. Clarke , Phillip Beale , Godefridus J. Peters

{"title":"Thymidylate synthase inhibitors","authors":"Stephen P. Ackland , Stephen J. Clarke , Phillip Beale , Godefridus J. Peters","doi":"10.1016/j.uct.2006.09.001","DOIUrl":"10.1016/j.uct.2006.09.001","url":null,"abstract":"<div>Despite the development of a range of exciting novel agents in cancer therapy, thymidylate synthase (TS) inhibitors remain pivotal in the management of many malignancies. Indeed, it can be said that TS inhibitors represent the first group of selectively targeted therapies used in cancer, since in the late 1950s the critical role of TS and thymidine to DNA synthesis were recognized and led to the rational development of fluoropyrimidines (FPs). Research in the last few years has expanded our knowledge of the TS gene and protein, and of the mechanism by which TS inhibition induces cell death, as well as the mechanism of action of various inhibitors of TS. This chapter highlights new insights and developments in the understanding of TS and its regulation, and in the preclinical and clinical development of TS inhibitors in the last 1–2 years. The most notable new information relates to molecular factors allowing better prediction of outcome from TS inhibition, use of FP-based combinations in adjuvant therapy of colorectal and lung cancers, and the increasing range of clinical applications for both antifolate TS inhibitors and fluoropyrimidines.</div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55738325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10